Among patients with relapsed or refractory AML, the ORR was 40.3%. Median OS was 9.3 months in 176 patients and 19.7 months in 34 patients with CR. In 130 patients with IDH2-R140 mutations, ORR was 35.4% while ORR was 53.3% in 45 patients with IDH2-R172 mutations. Here, IDH2 is linked to acute myeloid leukemia.